Referenceprogram for unipolar depression hos voksne

125. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland
RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M, STAR*D
Study Team. Evaluation of outcomes with citalopram for depression using measurement-based care in
STAR*D: Implications for clinical practice. Am J Psychiatry. 2006;163:28-40.
126. Khan A, Brodhead AE, Kolts RL, Brown WA. Severity of depressive symptoms and response to
antidepressants and placebo in antidepressant trials. J Psychiatr Res. 2005;39:145-150.
127. Stage KB. Depression. Rational Farmakoterapi. 2001;12:1-4.
128. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major
depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine
XR: A meta-analysis. J Psychiatry Neurosci. 2006;31:122-131.
129. Thase ME, Entsuah AR, Rudolph RL. Remission rates during treatment with venlafaxine or
selective serotonin reuptake inhibitors. Br J Psychiatry. 2001;178:234-241.
130. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of
venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: A metaanalysis.
Br J Psychiatry. 2002;180:396-404.
131. Mallick R, Chen J, Entsuah AR, Schatzberg AF. Depression-free days as a summary measure of
the temporal pattern of response and remission in the treatment of major depression: A comparison of
venlafaxine, selective serotonin reuptake inhibitors, and placebo. J Clin Psychiatry. 2003;64:321-330.
132. Montgomery SA, Huusom AK, Bothmer J. A randomised study comparing escitalopram
with venlafaxine XR in primary care patients with major depressive disorder. Neuropsychobiology.
2004;50:57-64.
133. Bielski RJ, Ventura D, Chang CC. A double-blind comparison of escitalopram and venlafaxine
extended release in the treatment of major depressive disorder. J Clin Psychiatry. 2004;65:1190-1196.
134. Goldstein DJ, Mallinckrodt C, Lu Y, Demitrack MA. Duloxetine in the treatment of major
depressive disorder: A double-blind clinical trial. J Clin Psychiatry. 2002;63:225-231.
135. Goldstein DJ, Lu Y, Detke MJ, Wiltse C, Mallinckrodt C, Demitrack MA. Duloxetine in
the treatment of depression: A double-blind placebo-controlled comparison with paroxetine. J Clin
Psychopharmacol. 2004;24:389-399.
136. Detke MJ, Wiltse CG, Mallinckrodt CH, McNamara RK, Demitrack MA, Bitter I. Duloxetine in
the acute and long-term treatment of major depressive disorder: A placebo- and paroxetine-controlled
trial. Eur Neuropsychopharmacol. 2004;14:457-470.
137. Bech P, Kajdasz DK, Porsdal V. Dose-response relationship of duloxetine in placebo-controlled
clinical trials in patients with major depressive disorder. Psychopharmacology (Berl). 2006;188:273-280.
138. Tignol J, Stoker MJ, Dunbar GC. Paroxetine in the treatment of melancholia and severe
depression. Int Clin Psychopharmacol. 1992;7:91-94.
139. Bech P, Andersen HF, Wade A. Effective dose of escitalopram in moderate versus severe DSM-IV
major depression. Pharmacopsychiatry. 2006;39:128-134.
Referenceprogram for unipolar depression hos voksne 111